J&J Said to Boost Offer to Settle Baby Powder Lawsuits to Over $8.2B
Harris In Trouble? New Swing State Poll Shows Trump Gains Ground In Key Battleground Areas For 2024 Election
Abbott Laboratories' Attractive Valuation Ranks It Among Top Large-Cap MedTech Companies, Says Analyst
BioNTech Analyst Ratings
Tandem Diabetes Rises as Insulin Pump Cleared for Use in EU With Lilly Insulin
Abbott a New Overweight at Piper Sandler; at Attractive Entry Point
103648771 : If you check the company profile you would find: 1. Company making losses over the years.
2. Does not hit market expectations most of the time.
3. For pharmaceutical, they rely of drugs r and d very much. Type of drugs and result is the key.